{"id":"entecavir-lamivudine","safety":{"commonSideEffects":[{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatomegaly"},{"rate":null,"effect":"Elevated transaminases"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are nucleoside analogues that get incorporated into the growing viral DNA chain during HBV replication, causing chain termination and preventing further viral DNA synthesis. Lamivudine was the first-line agent historically, while entecavir is a more potent second-generation inhibitor with a higher genetic barrier to resistance. This combination targets the same enzyme but may provide additive or synergistic antiviral effects.","oneSentence":"Entecavir and lamivudine are nucleoside reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:33.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT05406089","phase":"","title":"Effects of Antiviral Therapy on Patients With HBV-related HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-01-01","conditions":"Hepatocellular Carcinoma, Hepatitis B Virus, Survival","enrollment":494},{"nctId":"NCT02862548","phase":"PHASE2","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-16","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT01943799","phase":"PHASE2","title":"Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-13","conditions":"Chronic HBV Infection","enrollment":178},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT02019966","phase":"","title":"A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-05-12","conditions":"The Difficult-to-treat Chronic Hepatitis B","enrollment":1020},{"nctId":"NCT01354652","phase":"PHASE4","title":"Lactic Acidosis During Entecavir(ETV)Treatment","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2011-05","conditions":"Lactic Acidosis","enrollment":5},{"nctId":"NCT01580202","phase":"PHASE3","title":"Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-04","conditions":"Malignancy, Hepatitis B","enrollment":180},{"nctId":"NCT01706575","phase":"PHASE2","title":"A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-01","conditions":"Hepatitis B, Chronic","enrollment":76},{"nctId":"NCT01627223","phase":"PHASE4","title":"Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation","status":"TERMINATED","sponsor":"Taichung Veterans General Hospital","startDate":"2012-07","conditions":"Chronic Hepatitis B","enrollment":17},{"nctId":"NCT02644538","phase":"PHASE4","title":"Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2015-12","conditions":"Hepatitis B","enrollment":196},{"nctId":"NCT02482272","phase":"PHASE4","title":"Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2015-05","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT01013272","phase":"NA","title":"Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2007-06","conditions":"Hepatitis B, Chronic","enrollment":50},{"nctId":"NCT02560649","phase":"PHASE4","title":"An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2015-05","conditions":"Chronic Hepatitis B","enrollment":324},{"nctId":"NCT00986778","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01720238","phase":"","title":"Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2012-03","conditions":"Liver Cirrhosis, Hepatitis B","enrollment":621},{"nctId":"NCT02005146","phase":"","title":"Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2013-12","conditions":"Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues","enrollment":86},{"nctId":"NCT00637663","phase":"PHASE4","title":"Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2008-02","conditions":"Hepatitis B, Chronic","enrollment":72},{"nctId":"NCT00393484","phase":"PHASE4","title":"A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-02","conditions":"Chronic Hepatitis B","enrollment":122},{"nctId":"NCT01046799","phase":"PHASE3","title":"Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir","status":"COMPLETED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2008-03","conditions":"Liver Transplantation, Hepatitis B, Liver Disease","enrollment":20},{"nctId":"NCT01546116","phase":"PHASE4","title":"Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)","status":"COMPLETED","sponsor":"Korea University","startDate":"2010-02","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT01023217","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-11","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT01597934","phase":"PHASE4","title":"Antiviral Efficacy of Switching to ETV Plus TDF","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":104},{"nctId":"NCT00410202","phase":"PHASE3","title":"Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Hepatitis B, Chronic","enrollment":629},{"nctId":"NCT01914744","phase":"PHASE2","title":"Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2013-02","conditions":"Non-Hodgkin Lymphoma, Hepatitis B Reactivation","enrollment":82},{"nctId":"NCT01894269","phase":"PHASE4","title":"Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-07","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT01844063","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2013-07","conditions":"Liver Failure","enrollment":210},{"nctId":"NCT00662545","phase":"PHASE4","title":"Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"HIV Infections, Hepatitis B","enrollment":10},{"nctId":"NCT01718587","phase":"PHASE1, PHASE2","title":"Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients","status":"UNKNOWN","sponsor":"General Hospital of Chinese Armed Police Forces","startDate":"2012-11","conditions":"Liver Cirrhosis","enrollment":60},{"nctId":"NCT00531167","phase":"PHASE4","title":"Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B","status":"COMPLETED","sponsor":"Korea University","startDate":"2007-04","conditions":"Chronic Hepatitis B","enrollment":219},{"nctId":"NCT01438424","phase":"PHASE2","title":"Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-01","conditions":"Hepatitis B Virus, HBV","enrollment":1053},{"nctId":"NCT01595633","phase":"PHASE4","title":"Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-03","conditions":"Chronic Hepatitis B","enrollment":124},{"nctId":"NCT00625339","phase":"PHASE4","title":"Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-02","conditions":"Hepatitis B, Chronic","enrollment":72},{"nctId":"NCT00625560","phase":"PHASE4","title":"Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-02","conditions":"Hepatitis B, Chronic","enrollment":72},{"nctId":"NCT01337479","phase":"","title":"A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-02","conditions":"Hepatitis B","enrollment":1097},{"nctId":"NCT00036608","phase":"PHASE3","title":"A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-01","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT00035789","phase":"PHASE3","title":"A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT00051038","phase":"PHASE2, PHASE3","title":"Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-09","conditions":"Hepatitis B","enrollment":""},{"nctId":"NCT00035633","phase":"PHASE3","title":"A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-12","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT01037166","phase":"PHASE2","title":"Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT00823550","phase":"PHASE4","title":"Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2009-01","conditions":"Hepatitis B, Chronic","enrollment":462},{"nctId":"NCT00605384","phase":"PHASE3","title":"A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT01155427","phase":"","title":"Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Hepatitis B, Chronic","enrollment":100},{"nctId":"NCT01139203","phase":"NA","title":"Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-08","conditions":"Liver Transplantation, Hepatitis B","enrollment":300},{"nctId":"NCT01022801","phase":"PHASE2","title":"A Phase II Dose Response Study in Japan in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-08","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT00555334","phase":"PHASE4","title":"Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-11","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":200},{"nctId":"NCT00768157","phase":"PHASE4","title":"Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-04","conditions":"Hepatocellular Carcinoma, Hepatitis B Virus, Recurrence","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Entecavir:baraclude","Lamivudine: zeffix"],"phase":"marketed","status":"active","brandName":"entecavir, lamivudine","genericName":"entecavir, lamivudine","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Entecavir and lamivudine are nucleoside reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}